THE OBJECTION TO THE SPECIFICATION AND THE REJECTION OF CLAIMS 31-41 UNDER 35 U.S.C. 112, FIRST PARAGRAPH

Claims 31-41 are rejected as allegedly not enabled. The claims refer to particular known genes, but the genes are not described by nucleotide sequence. Rather, the genes are described by names. The specification further provides accession numbers for each of the genes in a database of sequences maintained by the U.S. government. The Office Action asserts that this is an attempt to incorporate by reference material that is essential to the practice of the claimed invention. Moreover, it asserts that this is an improper incorporation by reference since the material is not contained in an issued U.S. patent. This rejection is respectfully traversed.

Claim 31 has been amended in the current amendment to recite names of genes, rather than numbers referring to a figure. Thus there is no reference at all to anything outside of the claims, let alone an improper reference or an improper incorporation by reference.

It is respectfully submitted that one of ordinary skill in the art would be able to practice the invention without recourse to undue experimentation. Each of the genes is known in the art, as evidenced by its accession number in a public database. The rejection fails to point out what aspect of the invention would require undue experimentation.

The claims are enabled because one of ordinary skill in the art could practice the invention without recourse to undue experimentation. Moreover, the claims contain no improper incorporation by reference of essential material because the claims contain no reference to other material. Withdrawal of this rejection is respectfully requested.

REJECTION OF CLAIMS 31-41 UNDER THE JUDICIALLY CREATED DOCTRINE OF DOUBLE PATENTING

Claims 31-41 are rejected as unpatentable over claims 1-24 of U.S. Patent No. 6,020,135. This rejection is respectfully traversed.

U.S. Patent No. 6,020,135 issued from application serial no. 09/049,025. During the prosecution of the reference application a restriction requirement was issued. Communication dated 12/21/98, attached. The restriction requirement designated claims 44-45 as claim group

IV. These claims were elected and issued in the 6,020,135 patent. The same restriction requirement designated claims 31-41 (currently under examination in the subject application) as claim group II. The Communication designated these claims as patentably distinct inventions. See page 2. Specifically, the Communication stated that "[i]nventions II and IV are drawn to two independent and distinct processes which have different goals, different intermediate steps and different end results." See page 3. Moreover, "they have acquired a separate status in the art as shown by their different classification." *Ibid.* Thus this rejection appears to be based on a conclusion which is directly opposite to that taken previously by the Patent Office in a parent application. Applicants relied on the restriction requirement in filing the subject divisional application.

35 U.S.C. 121 mandates that claims issuing from one of a restricted group of claims cannot be used to reject claims of another of the restricted group of claims in a divisional application. Nonetheless, that appears to be the basis for the current rejection. Thus this rejection appears to violate section 121.

Applicants request that the Patent Office reconsider the propriety of this rejection in view of the restriction requirement issued in the 6,020,135 patent. If the rejection is deemed improper, as applicants believe it is, it should be withdrawn.

Respectfully submitted,

Sarah A. Kagan

Registration No. 32,141

BANNER & WITCOFF, LTD. Eleventh Floor 1001 G Street, N.W. Washington, D.C. 20001 (202) 508-9100

Thereads 5

BANNER AND WITCOFF



UNITED STATES D. ARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

FIRST NAMED INVENTOR APPLICATION NO. FILING DATE ATTORNEY DOCKET NO. **T**9/640.025

HM01/1221

EXAMINER

SARAH & RAGAN BANNER & WITCHEF 1001 G STREET NW WASHINGTON IN 20001-4597

ART UNIT

PAPER NUMBER

RECEIVED

DATE MAILED:

12/21/98

DEC 2 9 1998

BANNER & WITCOFF LTD.

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

:#14-11°

Application No.

Applicant(s)

*	09/049,025	Levi	Levine et al.	
Office Action Summary	Examiner	Group Art	# 14 B F F LIKE B B LIKE B B B LIKE B B B B B B B B B B B B B B B B B B	
	Ethan Whisena	int 1634		
Responsive to communication(s) filed on		1997 P. T.	- 42.	
			Mag-	
☐ This action is FINAL.	21	A STATE OF THE STA	,	
Since this application is in condition for allowance excessin accordance with the practice under Ex parte Quayle,	1935 C.D. 11; 453 O	.G. 213,,,,	\$ P	
A shortened statutory period for response to this action is is longer, from the mailing date of this communication. Fai application to become abandoned. (35 U.S.C. § 133). Ext. 37 CFR 1.136(a).	lure to respond within	the period for respo	gse will cause the	
Disposition of Claims	·- · · · · · · · · · · · · · · · · ·	**		
Claim(s) 1-66	~ ·	is/are pending in	the application.	
Of the above, claim(s)	-	is/are withdrawn f	rom consideration.	
☐ Claim(s)		is/are allow		
Claim(s)	· · · · · · · · · · · · · · · · · · ·			
☐ Claim(s)				
☑ Claims 1-66		to restriction or elec		
	7			
Application Papers See the attached Notice of Draftsperson's Patent Draftsperson's Pate	awing Review, PTO:9	-		
☐ The drawing(s) filed on is/are c		**		
The proposed drawing correction, filed on		* · · ·	ed.	
The specification is objected to by the Examiner.		un		
☐ The path or declaration is objected to by the Examin	er.	Č:	PTRAIN NAME .	
Priority under 35 U.S.C. § 119		· ·	* ***	
Acknowledgement is made of a claim for foreign pri	ority under 35 U.S.C.	§ 119(a)-(d).	19 (ka)	
☐ All ☐ Some* ☐ None of the CERTIFIED cop		The state of the s		
☐ received.		ch.		
received in Application No. (Series Code/Seria	l Number)	<u>, 21</u> 10	removed to	
received in this national stage application from	the International Bur	eau (PCT Rule 17.2(a)).	
*Certified copies not received:		-12 × 50°	450	
Acknowledgement is made of a claim for domestic	priority under 35 U.S.(C. § 14,9(e).	•466	
	•			
Attachment(s)		.87°	,	
Notice of References Cited, PTO-892	ser Note)	***	was a series	
Information Disclosure Statement(s), PTO-1449, Pap	(A)	#4		
 Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Review, PT 	∩-948	. 17.0		
☐ Notice of Informal Patent Application, PTO-152	Q Q TO		Silver V	
□ Motice of informative entrophocology (10-102	-			
A contract of the contract of			. •	

- SEE OFFICE ACTION ON THE FOLLOWING PAGES -

Serial Number: 09/049,025

Art Unit: 1634

Z

ELECTION/RESTRICTION

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-30, 64-66, drawn to a method of diagnosing cancer or determining p53 status in a sample suspected of being neoplastic, classified in Class 435, subclass 6 and/or subclass 7.1.
 - Claims 31-41, drawn to a method of evaluating the carcinogenicity of an agent, classified in
 Class 524, subclass 9.2.
 - III. Claims 42-43, drawn to a method of treating cancer, classified in Class 514, subclass 44,
 - IV. Claims 44-45, drawn to a method of screening drugs for utility as agents to treat cancer, classified in Class 524, subclass 9.2.
 - V. Claims 46-63, drawn to a set of olgonucleotide probes which hybridize to p53 regulated genes, classified in Class 536, subclasses 23.1 and 24.3.
- 2. The following explains why the groups above are patentably distinct inventions.

Inventions I and II are drawn to two independent and distinct processes which have different goals, different intermediate steps and different end results.

Inventions I and III are drawn to two independent and distinct processes which have different goals, different intermediate steps and different end results.

Inventions I and IV are drawn to two independent and distinct processes which have different goals, different intermediate steps and different end results.

Inventions I and V are related as a process and product. The product in this case (Invention V), can be used in the process of Invention I, however, it may also be used in a materially different.



Serial Number: 09/049,025

Art Unit: 1634

process for using the product. For example, the oligonucleotides of Group V may be used as molecular weight markers in gel electrophoresis.

Inventions II and III are drawn to two independent and distinct processes which have different goals, different intermediate steps and different end results.

Inventions II and IV are drawn to two independent and distinct processes which have different goals, different intermediate steps and different end results.

Inventions II and V are related as a process and product. The product in this case (Invention V), can be used in the process of Invention II, however, it may also be used in a materially different process for using the product. For example, the oligonucleotides of Group V may be used as molecular weight markers in gel electrophoresis.

Inventions III and IV are drawn to two independent and distinct processes which have different goals, different intermediate steps and different end results.

Inventions III and V are related as a process and product. The product in this case (Invention V), can be used in the process of Invention III, however, it may also be used in a materially different process for using the product. For example, the oligonucleotides of Group V may be used as molecular weight markers in gel electrophoresis.

Inventions IV and V are related as a process and product. The product in this case (Invention V), can be used in the process of Invention IV, however, it may also be used in a materially different process for using the product. For example, the oligonucleotides of Group V may be used as molecular weight markers in gel electrophoresis.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 4. A telephone call was made to Sarah Kagan on 8 DEC 98 to request an oral election to the above restriction requirement, but did not result in an election.



Serial Number: 09/049,025

Art Unit: 1634

The applicant is advised that the response to this requirement, to be complete, must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

- Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee mequired under 37 CFR 1.17(h).
- Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ethan Whisenant, Ph.D whose telephone number is (703) 308-6567. The examiner can normally be reached Monday-Friday from 8:00AM-4:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached at (703) 308-1152.

The fax number for this Group is (703) 305-3014. Please note that the faxing of papers must conform with the Notice to Comply published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Any inquiry of a general nature or relating to the status of this application should be directed to the group receptionist whose telephone number is (703) 308-0196.

ECW

Ethan Whisenant, Ph.D. Patent Examiner

W. Gary Jones
Supervisory Patent Examiner

Technology Center 1,600